The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | The potential benefits of fixed-duration bispecific antibody therapy in multiple myeloma
Ravi Vij, MD, MBA, Washington University School of Medicine, St. Louis, MO, discusses the potential for fixed-duration bispecific antibody therapy to provide durable responses without continuous treatment in relapsed/refractory multiple myeloma. He highlights the potential to reduce infection risk and T-cell exhaustion by limiting treatment exposure, while emphasizing the need for further studies to determine whether these findings extend to other bispecific antibodies and targets.This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think that the treatment-free interval concept is coming back to the therapy in multiple myeloma. In multiple scenarios, we are certainly talking about limiting the duration of maintenance therapy, post-autologous stem cell transplant, and with bispecifics too, as these drugs usually produce deep responses very quickly, the paradigm of fixed-duration treatment is definitely one that is very attractive because we know that the longer the drugs are administered, the more the risk for infections...
I think that the treatment-free interval concept is coming back to the therapy in multiple myeloma. In multiple scenarios, we are certainly talking about limiting the duration of maintenance therapy, post-autologous stem cell transplant, and with bispecifics too, as these drugs usually produce deep responses very quickly, the paradigm of fixed-duration treatment is definitely one that is very attractive because we know that the longer the drugs are administered, the more the risk for infections. And also, at least in the laboratory, the greater the risk for T-cell exhaustion. So I think that this is one of the few prospective data sets that we have available today that seem to suggest that treatment to progression may not be needed in patients. Obviously, we will need to have more data sets to be able to be sure that this experience transfers over to the other bispecific antibodies to other targets.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
